SCHEMBL650124

SCHEMBL650124

Cc1cc(O)ccc1/N=C1/NC(=O)/C(=C/c2cnc(NCCCN3CCOCC3)s2)S1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.42
MAPT P10636 5/20 0.42
MEN1 O00255 4/20 0.42
MAPK1 P28482 2/20 0.42
PKM P14618 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
NPSR1 Q6W5P4 3/20 0.40
TDP1 Q9NUW8 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
RECQL P46063 1/20 0.39
RNASEL Q05823 1/20 0.39
LCK P06239 2/20 0.38
LMNA P02545 1/20 0.38
POLB P06746 2/20 0.37
HPGD P15428 1/20 0.37
CDC25B P30305 2/20 0.37
PTPN1 P18031 1/20 0.37
PIK3CD O00329 1/20 0.36
PIK3CA P42336 1/20 0.36
PIK3CB P42338 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL650125 1.00 KMT2A (0.42) KMT2AMAPTMEN1MAPK1PKM
SCHEMBL10176363 0.93 MAPT (0.41) KMT2AMAPTMEN1MAPK1PKM
SCHEMBL650930 0.92 MAPT (0.48) KMT2AMAPTMEN1MAPK1PKM
SCHEMBL650929 0.92 MAPT (0.48) KMT2AMAPTMEN1MAPK1PKM
SCHEMBL648672 0.85 CDC25A (0.43) KMT2AMAPTMEN1MAPK1PKM
SCHEMBL649998 0.85 CDC25A (0.43) KMT2AMAPTMEN1MAPK1PKM
SCHEMBL653415 0.85 MAPT (0.50) KMT2AMAPTMEN1MAPK1PKM
SCHEMBL10226368 0.85 MAPT (0.50) KMT2AMAPTMEN1MAPK1PKM
SCHEMBL10227773 0.85 MAPT (0.42) KMT2AMAPTMEN1MAPK1NPSR1
SCHEMBL10227586 0.85 MAPT (0.41) KMT2AMAPTMEN1MAPK1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2423204-A1 THIAZOLIDINONE DERIVATIVE SBI Biotech Co., Ltd. (JP) 2012-02-29 EP disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed
WO-2010122979-A1 THIAZOLIDINONE DERIVATIVE SBIバイオテック株式会社 (JP) 2010-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE CDC7, CDK17, CDCA2 KMT2A 3437/4885MAPT 3657/4885MEN1 1406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.